Ozempic & Blood Sugar: What to Know Before You Start

GLP-1 receptor agonists have become some of the most widely discussed medications in blood sugar management. Among them, Ozempic (semaglutide) has drawn significant attention from both healthcare providers and the general public. If your doctor has mentioned it or you've simply seen the headlines, you probably have questions about how it works, what the research says and what side effects to expect.

This guide walks through the published evidence on semaglutide and blood sugar. It covers the mechanism, the key clinical trials, the common side effects and the questions worth asking your healthcare provider. Nothing here is medical advice. It's an educational overview to help you prepare for that conversation.

This guide is general education. If you use insulin or other glucose medicines, follow the plan your diabetes team gave you.

What is Ozempic and how does it affect blood sugar?

Ozempic is a brand name for semaglutide, a GLP-1 receptor agonist approved by the FDA in 2017 for type 2 diabetes. In the SUSTAIN trial program, semaglutide reduced A1C by 1.0 to 1.8 percentage points (about 11 to 20 mmol/mol) over 30 to 56 weeks across multiple studies and doses.^[1] That size of A1C reduction is among the largest observed for any injectable non-insulin medication. Talk to your healthcare provider about whether this medication fits your needs.

How GLP-1 works in the body

GLP-1, or glucagon-like peptide-1, is a hormone your gut naturally releases after eating. It does three main things. First, it tells the pancreas to release more insulin when blood sugar is higher. Second, it signals the pancreas to reduce glucagon, a hormone that raises blood sugar. Third, it slows gastric emptying, meaning food leaves your stomach more gradually.^[5]

Natural GLP-1 breaks down within minutes. Semaglutide is engineered to last much longer. It stays active for roughly seven days, which is why Ozempic is a once-weekly injection. The extended half-life comes from structural modifications that help it bind to albumin in the blood and resist enzymatic breakdown.^[6]

Why blood sugar drops aren't the whole story

GLP-1 receptor agonists affect more than glucose numbers. They also reduce appetite through brain signaling, which often leads to weight loss. In SUSTAIN-6, participants on the 1.0 mg dose lost an average of 4.3 kg (9.5 lb) over two years.^[7] That weight change itself may support improved insulin sensitivity in muscle and liver cells. But these are secondary effects. The primary reason doctors prescribe Ozempic is blood sugar management.

Before your appointment, write down your current A1C, any medications you're taking and your main concerns. Research has found that patients who bring written questions to appointments get more of their concerns addressed. Preparation helps you and your doctor make better decisions together.^[8]

What did the SUSTAIN trials actually find?

The SUSTAIN clinical trial program included more than 8,000 participants across multiple randomized controlled trials. SUSTAIN-1 through SUSTAIN-10 tested semaglutide against placebo and active comparators at doses of 0.5 mg and 1.0 mg weekly. These trials form the foundation of what we know about Ozempic's efficacy and safety profile. The SUSTAIN trials were funded by Novo Nordisk, the manufacturer of Ozempic.^[9]

SUSTAIN-1: semaglutide versus placebo

In SUSTAIN-1, adults with type 2 diabetes who were not on other diabetes medicines received semaglutide 0.5 mg, 1.0 mg or placebo for 30 weeks. The 0.5 mg group saw an average A1C reduction of 1.45% (about 16 mmol/mol) and the 1.0 mg group saw a 1.55% reduction (about 17 mmol/mol). Placebo came in at 0.02%.^[1] Those are large effect sizes for a single medication.

SUSTAIN-2: added to metformin

SUSTAIN-2 compared semaglutide to sitagliptin (Januvia) in people already on metformin. Over 56 weeks semaglutide produced greater A1C reductions than sitagliptin at both doses. Weight loss was also greater in the semaglutide group.^[10] This trial showed semaglutide's effectiveness as an add-on to existing metformin therapy.

SUSTAIN-6: cardiovascular outcomes

SUSTAIN-6 was a two-year cardiovascular outcomes trial involving 3,297 participants with type 2 diabetes and high cardiovascular risk. Semaglutide reduced major adverse cardiovascular events (MACE) by 26% compared to placebo.^[7] This finding was significant because it showed benefits beyond blood sugar reduction. The FDA later approved Ozempic to reduce the risk of major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease.

The four main SUSTAIN trials at a glance

Trial and comparison.	Participants and duration.	Key A1C or weight finding.	Main takeaway.
SUSTAIN-1, versus placebo.[1]	388 adults not taking other glucose medicines, 30 weeks.[1]	A1C fell 1.45% (16 mmol/mol) on 0.5 mg and 1.55% (17 mmol/mol) on 1.0 mg, versus 0.02% on placebo.[1]	A large drop when used as the only medicine.[1]
SUSTAIN-2, versus sitagliptin.[10]	1,231 adults on metformin, thiazolidinediones or both, 56 weeks.[10]	A1C fell 1.3% (14 mmol/mol) and 1.6% (17 mmol/mol), versus 0.5% (5 mmol/mol). Weight fell 4.3 kg (9.5 lb) and 6.1 kg (13.4 lb), versus 1.9 kg (4.2 lb).[10]	More A1C and weight change than a daily DPP-4 tablet.[10]
SUSTAIN-6, cardiovascular outcomes.[7]	3,297 adults at high cardiovascular risk, about 2 years.[7]	Heart attack, stroke or cardiovascular death in 6.6% versus 8.9% on placebo, a 26% smaller risk.[7]	Heart benefit, with more eye complications to watch for.[7]
SUSTAIN-7, versus dulaglutide.[11]	1,201 adults on metformin, 40 weeks.[11]	A1C fell 1.5% (16 mmol/mol) and 1.8% (20 mmol/mol), versus 1.1% (12 mmol/mol) and 1.4% (15 mmol/mol). Weight fell 4.6 kg (10.1 lb) and 6.5 kg (14.3 lb), versus 2.3 kg (5.1 lb) and 3.0 kg (6.6 lb).[11]	More A1C and weight change than another weekly GLP-1.[11]

mmol/mol figures are approximate conversions of the percentage-point changes reported in each trial.

Clinical trial results reflect averages across thousands of participants. Your individual response may be larger or smaller. The American Diabetes Association recommends checking A1C at least twice a year, and about every 3 months after a treatment change or when you are not at your goal. That is how you see whether a medicine is working for you.^[4]

What are the common side effects of Ozempic?

Gastrointestinal side effects are the most frequently reported issue with semaglutide. In the pooled placebo-controlled trials on the US label, nausea occurred in 16% of people on 0.5 mg and 20% on 1 mg (6% on placebo), vomiting in 5 to 9% and diarrhea in about 9%.^[2] A review of all GLP-1 drugs found that every one of them raises the risk of stomach side effects.^[12] Most of these symptoms appeared during the dose-escalation phase and decreased over time. Your doctor can help manage side effects if they arise.

The dose-escalation approach

Ozempic starts at 0.25 mg weekly for the first four weeks, then increases to 0.5 mg. If needed, the dose rises to 1 mg after at least four more weeks and then to 2 mg after at least four weeks on 1 mg. The US prescribing information lists 2 mg weekly as the highest dose.^[2] The UK SmPC says the same and advises against weekly doses above 2 mg.^[13] This gradual increase is designed to give the body time to adjust. An early phase 2 dose-finding study found that GI side effects were more common at higher doses and that a stepwise start made them easier to tolerate.^[14] Some doctors extend the escalation period for patients who are more sensitive.

Less common but serious concerns

Pancreatitis has been reported in a small number of GLP-1 receptor agonist users. It is listed as a warning on the label, and anyone who develops severe, persistent abdominal pain should stop the medication and get medical care.^[2] Semaglutide carries a boxed warning about medullary thyroid carcinoma (MTC) based on animal studies. This hasn't been confirmed in humans. The US label lists it as contraindicated in people with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2.^[2]

The label also warns about diabetic retinopathy, the eye damage diabetes can cause. In SUSTAIN-6, eye complications from retinopathy occurred in 3.0% of people on Ozempic and 1.8% on placebo. The difference was larger in people who already had retinopathy, and a rapid improvement in blood sugar has been linked to a temporary worsening. If you have a history of retinopathy, ask how your eyes will be checked while you start.^[2]

Ozempic slows how quickly the stomach empties. There have been rare reports of stomach contents being breathed into the lungs during procedures under general anesthesia or deep sedation, even in people who had fasted. Tell the healthcare team about any planned surgery or procedure if you take Ozempic.^[2]

Semaglutide is also not recommended during pregnancy, and the US and UK labels advise stopping it at least 2 months before a planned pregnancy because of its long washout period.^[2][13]

Hypoglycemia risk

When used alone or with metformin, semaglutide has a small risk of hypoglycemia because its insulin-stimulating effect depends on blood glucose levels.^[2][5] However, if Ozempic is combined with insulin or a sulfonylurea such as gliclazide or glimepiride, your blood sugar can fall too low unless your prescriber reduces the dose of those medicines.^[2][13] Low blood sugar usually means below 4 mmol/L (72 mg/dL) in the UK or below 70 mg/dL (3.9 mmol/L) in the US.^[15][16] Our guide to low blood sugar covers the warning signs. In the UK, the NHS says to call 999 if someone may have very low blood sugar and is not responding normally or is unconscious, and a glucagon injection is not available or you do not know how to use it, or they have not recovered within 10 minutes of a glucagon injection, or they have been drinking alcohol.^[15] In the US, the ADA says to call 911 right away if someone is unconscious and glucagon is not available or no one knows how to use it.^[16]

How does Ozempic compare to other blood sugar medications?

The American Diabetes Association's 2026 Standards of Care say the choice of medicine should be made with your doctor, weighing its effects on the heart, kidneys and weight. Metformin has historically been the first-line medicine for type 2 diabetes and is still widely used because it is effective, safe and inexpensive. For people with chronic kidney disease, the 2026 Standards name semaglutide as another first-line option.^[3] GLP-1 receptor agonists like semaglutide are also considered when metformin alone isn't sufficient or when cardiovascular or weight-related benefits are priorities. No single medication fits everyone. The right choice depends on your individual profile.

Semaglutide versus other GLP-1 agonists

Semaglutide isn't the only GLP-1 receptor agonist. Others include liraglutide (Victoza), dulaglutide (Trulicity) and exenatide (Byetta/Bydureon). The SUSTAIN-7 trial compared semaglutide head-to-head against dulaglutide and found semaglutide produced greater A1C reductions (1.5 to 1.8% versus 1.1 to 1.4%) and more weight loss.^[11] But efficacy is just one factor. Cost, insurance coverage, injection frequency and tolerability all matter when choosing a medication with your doctor.

Semaglutide versus SGLT2 inhibitors

SGLT2 inhibitors (like empagliflozin and dapagliflozin) bring glucose down by causing the kidneys to excrete more glucose in urine. They also reduce heart failure risk. A network meta-analysis published in the BMJ found GLP-1 agonists and SGLT2 inhibitors have comparable cardiovascular benefits but work through different mechanisms.^[17] Some patients use both classes together. Ask your healthcare provider which approach fits your risk factors.

Cost is a real factor. Without insurance, Ozempic can be expensive in the US, often running to many hundreds of dollars per month. The manufacturer offers savings cards for commercially insured patients. If cost is a barrier, discuss alternatives with your doctor. Generic semaglutide is not available in the US.^[3]

Does lifestyle still matter when taking Ozempic?

Yes. The Diabetes Prevention Program found that lifestyle changes alone reduced progression to type 2 diabetes by 58% in people with prediabetes. That figure has held up in 15-year follow-up data.^[18] Medication and lifestyle aren't competing strategies. They're complementary. Your doctor will likely recommend continuing or starting lifestyle modifications regardless of which medications you take.

Diet and blood sugar while on semaglutide

Semaglutide slows gastric emptying, which means food sits in your stomach longer. Some people find they need smaller meals to avoid discomfort. There is no large trial of diet on top of semaglutide yet. In the SCALE Diabetes trial of liraglutide, an older GLP-1 drug, people on a reduced-calorie diet and exercise plan lost more weight with the drug than with diet and exercise alone.^[19] A registered dietitian can help you adjust meal timing and portion sizes.

Exercise and GLP-1 therapy

Physical activity supports insulin sensitivity through pathways that don't overlap with GLP-1 signaling. A review of exercise and insulin sensitivity found that aerobic and resistance training may improve insulin sensitivity for up to 48 hours after each session.^[20] That means exercise may add to semaglutide's effects rather than duplicate them. A short walk after meals is an easy place to start.

Sleep, stress, and the bigger picture

Sleep deprivation and chronic stress both impair insulin sensitivity independently of diet or exercise. Research in The Lancet found that sleeping only 4 hours per night for six nights clearly impaired glucose tolerance in healthy young men. No medication fully offsets those effects. Supporting your body through good sleep hygiene and stress management may help you get the most from any diabetes medication.^[21]

What about Ozempic for weight loss without diabetes?

Semaglutide at a higher dose (2.4 mg, branded as Wegovy) is FDA-approved for chronic weight management. The STEP-1 trial found that participants without diabetes lost an average of 14.9% of their body weight over 68 weeks. STEP-1 was funded by Novo Nordisk.^[22] This is a different indication and a different dose. It also calls for a different conversation with your doctor. Using Ozempic off-label for weight loss without medical supervision carries risks that may not be immediately obvious.

Why this distinction matters

Ozempic (0.25 mg to start, then 0.5 mg, 1 mg or 2 mg weekly) is approved for type 2 diabetes in both the US and the UK. Wegovy (2.4 mg) is approved for weight management. Insurance coverage, dosing and monitoring differ between the two. Talk to your healthcare provider about the appropriate indication for your situation.

What does the long-term research say?

SUSTAIN-6 provided two years of safety data. The SELECT trial (completed in 2023) studied semaglutide 2.4 mg in over 17,600 adults with obesity and cardiovascular disease for up to five years. SELECT found a 20% reduction in major adverse cardiovascular events. SELECT was funded by Novo Nordisk.^[23] These are encouraging signals but they still represent a relatively short window for a medication many people may take for decades. Ongoing research will fill in the longer-term picture.

Durability of effects

One important finding: the STEP-1 extension study showed that when participants stopped semaglutide, they regained roughly two-thirds of the weight they had lost within a year.^[24] A1C levels also tended to drift back up. This suggests that semaglutide manages blood sugar and weight while being taken rather than inducing permanent changes. Your doctor can discuss whether long-term use makes sense for your situation.

Kidney outcomes: the FLOW trial

The FLOW trial enrolled 3,533 people with type 2 diabetes and chronic kidney disease and gave them semaglutide 1.0 mg weekly or placebo. FLOW was funded by Novo Nordisk. Over a median of 3.4 years, the risk of major kidney disease events was 24% smaller with semaglutide.^[25] These events included kidney failure, a large fall in kidney function and death from kidney or heart causes. The US label now includes reducing the risk of kidney decline, end-stage kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease.^[2]

What researchers are still studying

Active research areas include semaglutide's effects on non-alcoholic fatty liver disease (NAFLD) and cognitive function. Early data from smaller trials suggest potential benefits in fatty liver reduction.^[26] But these areas need larger, longer studies before firm conclusions can be drawn. Science moves gradually.

Putting it all together

Ozempic is a well-studied medication with strong clinical trial data supporting its use in type 2 diabetes blood sugar management. The SUSTAIN program showed meaningful A1C reductions, cardiovascular benefits and a side effect profile that most people can manage with proper dose escalation. But it's not a decision to make from a blog article.

If you're interested, the right next step is a conversation with your healthcare provider. Bring your questions. Bring your current labs. Ask about your specific risk factors, insurance coverage and whether lifestyle changes alone might be sufficient for your goals. Informed patients tend to have better outcomes.

1. Write down your current HbA1c, your kidney and eye history, and all medicines you take before your appointment.^[2][8][27]
2. Start at the 0.25 mg once-weekly starter dose and step up gradually every 4 weeks as guided by your prescriber to reduce nausea.^[2][13][14]
3. Ask your prescriber whether your insulin or sulfonylurea dose needs to be reduced when starting Ozempic to prevent low blood sugar.^[2][13][15]
4. Tell your surgical or dental team that you take semaglutide before any procedure using general anesthesia or deep sedation.^[2][13]
5. Keep up balanced meals, regular physical activity and sleep habits alongside your weekly injection, and never stop your medicine without medical advice.^[18][20][24]

Blood sugar management is a long-term process. It is never a single decision. The fundamentals of diet, exercise, sleep and regular monitoring matter with or without semaglutide in your plan.

Questions to ask your diabetes team

• Given my HbA1c, heart and kidney profile, and medical history, does semaglutide fit my treatment plan, or do I have any contraindications such as a history of pancreatitis or medullary thyroid cancer?^[2][3][25]
• If I start Ozempic, do you need to reduce my insulin or sulfonylurea dose to prevent hypos, and should I have my eyes checked first if I have diabetic retinopathy?^[2][7][15]
• How will we step up the dose if I get nausea, and what is the rule if I miss a weekly injection (taking it within 5 days)?^[2][13][14]
• How often will we recheck my HbA1c and kidney function, and what severe symptoms (such as persistent stomach pain) mean I should seek urgent care?^[2][4][25]

Frequently asked questions

How much does Ozempic reduce A1C?

In the SUSTAIN trials, A1C fell by about 1.0 to 1.8 percentage points, roughly 11 to 20 mmol/mol, over 30 to 56 weeks. Your own result may be larger or smaller.^[1][9]

What happens if I miss a dose?

Take the missed dose as soon as you can, within 5 days. If more than 5 days have passed, skip it and take the next dose on your usual day.^[2]

Do blood sugar and weight go back up if you stop Ozempic?

They can. In the STEP 1 extension, adults without diabetes who stopped semaglutide 2.4 mg regained about two-thirds of the weight they had lost within a year, and most heart and metabolic measures, blood sugar included, moved back towards where they started.^[24] Do not stop without talking to your doctor first.

Can Ozempic cause low blood sugar?

On its own the risk is low, because it mainly works when blood sugar is high. The risk goes up when it is taken with insulin or a sulfonylurea, and your doctor may reduce the dose of those medicines.^[2]

What A1c do you need to get Ozempic?

The FDA label names no A1C cut-off. It lists Ozempic as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.^[2] Your doctor decides whether it fits you, based on your history and your other medicines.

Can Ozempic cause blood sugar to rise?

The FDA label describes Ozempic as a medicine used to improve glycemic control in adults with type 2 diabetes, and it does not list a rise in blood sugar among the adverse reactions.^[2] Blood sugar can drift back up when semaglutide is stopped, as A1C levels tended to do after withdrawal in the STEP 1 extension.^[24] Talk to your doctor before you stop or change a dose.

Where to go next

For more on how diabetes medicines work and what your lab numbers mean, see:

• The HbA1c test, to understand the number Ozempic is meant to change.
• Metformin side effects, if you take metformin alongside it.
• Is Diabec legit?, for what is in our supplement and what it does not do.

Note: If you are pregnant, breastfeeding, or considering giving any supplement or herbal product to a child, consult your healthcare provider before making any changes to your diet, supplement routine, or prescribed medications.

Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Talk to your doctor before changing your diet, your activity or your medicines, and before starting any supplement.